Vanguard Group Inc. Boosts Stock Position in Organon & Co. (NYSE:OGN)

Vanguard Group Inc. increased its holdings in shares of Organon & Co. (NYSE:OGN - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,401,709 shares of the company's stock after purchasing an additional 218,165 shares during the period. Vanguard Group Inc. owned 11.80% of Organon & Co. worth $453,593,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Pacer Advisors Inc. raised its position in shares of Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after acquiring an additional 11,140,388 shares in the last quarter. Weiss Asset Management LP bought a new stake in shares of Organon & Co. in the 3rd quarter valued at about $32,966,000. Magnetar Financial LLC grew its position in shares of Organon & Co. by 560.2% in the 4th quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company's stock worth $25,878,000 after buying an additional 1,471,731 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Organon & Co. by 303.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company's stock valued at $23,762,000 after acquiring an additional 934,505 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Organon & Co. by 191.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 760,807 shares of the company's stock worth $11,382,000 after purchasing an additional 499,616 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Remove Ads

Organon & Co. Stock Performance

OGN traded down $1.42 during midday trading on Friday, hitting $13.04. 5,005,037 shares of the company were exchanged, compared to its average volume of 2,575,777. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of 3.91, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The company's 50 day simple moving average is $15.16 and its 200 day simple moving average is $15.99. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 1-year low of $13.00 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. As a group, sell-side analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 8.59%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on OGN. Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley lowered their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Organon & Co. has an average rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.